Connection

William Creasman to Neoplasm Recurrence, Local

Back to Details
This is a "connection" page, showing publications William Creasman has written about Neoplasm Recurrence, Local.
William Creasman
Connection Strength
1.259
Neoplasm Recurrence, Local
  1. Phase II trial of pyrazoloacridine in recurrent platinum-sensitive ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2002 Jan; 84(1):32-5.
    View in: PubMed
    Score: 0.160
  2. Evaluation of recombinant human interleukin-12 in patients with recurrent or refractory ovarian cancer: a gynecologic oncology group study. Gynecol Oncol. 2001 Jul; 82(1):7-10.
    View in: PubMed
    Score: 0.155
  3. Endometrial carcinoma recurrence according to race and ethnicity: An NRG Oncology/Gynecologic Oncology Group 210 Study. Int J Cancer. 2018 03 15; 142(6):1102-1115.
    View in: PubMed
    Score: 0.120
  4. Dysregulation of miR-181c expression influences recurrence of endometrial endometrioid adenocarcinoma by modulating NOTCH2 expression: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017 12; 147(3):648-653.
    View in: PubMed
    Score: 0.119
  5. Nonsteroidal Anti-inflammatory Drugs and Endometrial Carcinoma Mortality and Recurrence. J Natl Cancer Inst. 2017 03 01; 109(3):1-10.
    View in: PubMed
    Score: 0.115
  6. Recommendations regarding estrogen replacement therapy after treatment of endometrial cancer. Oncology (Williston Park). 1992 Jul; 6(7):23-6; discussion 26, 28.
    View in: PubMed
    Score: 0.083
  7. Early stage I carcinoma of the vulva treated with ipsilateral superficial inguinal lymphadenectomy and modified radical hemivulvectomy: a prospective study of the Gynecologic Oncology Group. Obstet Gynecol. 1992 Apr; 79(4):490-7.
    View in: PubMed
    Score: 0.081
  8. Phase II trial of cisplatin in advanced or recurrent cancer of the vagina: a Gynecologic Oncology Group Study. Gynecol Oncol. 1986 Jan; 23(1):101-4.
    View in: PubMed
    Score: 0.053
  9. Serum vascular endothelial growth factor C (VEGF-C) as a specific biomarker for advanced cervical cancer: Relationship to insulin-like growth factor II (IGF-II), IGF binding protein 3 (IGF-BP3) and VEGF-A [corrected]. Gynecol Oncol. 2005 Sep; 98(3):467-83.
    View in: PubMed
    Score: 0.052
  10. A comparison of medroxyprogesterone serum concentrations by the oral or intramuscular route in patients with persistent or recurrent endometrial carcinoma. Am J Obstet Gynecol. 1979 Nov 01; 135(5):647-50.
    View in: PubMed
    Score: 0.034
  11. Is positive pelvic lymphadenopathy a contraindication to radical surgery in recurrent cervical carcinoma? Gynecol Oncol. 1974 Dec; 2(4):482-5.
    View in: PubMed
    Score: 0.025
  12. Prognostic significance of hormone receptors in endometrial cancer. Cancer. 1993 Feb 15; 71(4 Suppl):1467-70.
    View in: PubMed
    Score: 0.022
  13. Adenocarcinoma of the uterine corpus. Curr Opin Obstet Gynecol. 1993 Feb; 5(1):80-3.
    View in: PubMed
    Score: 0.022
  14. Adjuvant radiotherapy following radical hysterectomy for patients with stage IB and IIA cervical cancer. Gynecol Oncol. 1990 Jun; 37(3):390-5.
    View in: PubMed
    Score: 0.018
  15. Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol. 1989 Apr; 33(1):68-70.
    View in: PubMed
    Score: 0.017
  16. Percutaneous nephrostomy in gynecologic oncology patients. Am J Obstet Gynecol. 1988 May; 158(5):1126-31.
    View in: PubMed
    Score: 0.016
  17. Management of endometrial adenocarcinoma stage I with surgical staging followed by tailored adjuvant radiation therapy. Clin Obstet Gynaecol. 1986 Dec; 13(4):751-65.
    View in: PubMed
    Score: 0.014
  18. Management of stage IA carcinoma of the cervix. Am J Obstet Gynecol. 1985 Sep 15; 153(2):164-72.
    View in: PubMed
    Score: 0.013
  19. Leiomyosarcoma of the uterus: clinicopathologic study of 21 cases. Gynecol Oncol. 1985 Jun; 21(2):220-7.
    View in: PubMed
    Score: 0.013
  20. Treatment of recurrent or advanced uterine sarcoma. A randomized trial of doxorubicin versus doxorubicin and cyclophosphamide (a phase III trial of the Gynecologic Oncology Group). Cancer. 1985 Apr 15; 55(8):1648-53.
    View in: PubMed
    Score: 0.013
  21. Computed tomography in evaluation of extrapelvic lymphadenopathy in carcinoma of the cervix. Obstet Gynecol. 1985 Jan; 65(1):73-6.
    View in: PubMed
    Score: 0.012
  22. The significance of peritoneal cytology in patients with carcinoma of the cervix. Gynecol Oncol. 1984 Feb; 17(2):139-48.
    View in: PubMed
    Score: 0.012
  23. Cryotherapy in the treatment of cervical intraepithelial neoplasia. Obstet Gynecol. 1983 Sep; 62(3):353-8.
    View in: PubMed
    Score: 0.011
  24. Phase II study of maytansine in the treatment of advanced or recurrent adenocarcinoma of the ovary. A Gynecologic Oncology Group study. Am J Clin Oncol. 1983 Jun; 6(3):273-5.
    View in: PubMed
    Score: 0.011
  25. Stage I borderline ovarian tumors. Obstet Gynecol. 1982 Jan; 59(1):93-6.
    View in: PubMed
    Score: 0.010
  26. The role of adjuvant therapy in Stage I ovarian cancer. Am J Obstet Gynecol. 1980 Sep 15; 138(2):139-45.
    View in: PubMed
    Score: 0.009
  27. A phase II trial of prolonged oral etoposide (VP-16) as second-line therapy for advanced and recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 1996 Oct; 63(1):101-4.
    View in: PubMed
    Score: 0.007
  28. Operative management of early invasive epidermoid carcinoma of the vulva. Am J Obstet Gynecol. 1975 Oct 15; 123(4):349-55.
    View in: PubMed
    Score: 0.007
  29. Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study. Cancer. 1993 Feb 15; 71(4 Suppl):1702-9.
    View in: PubMed
    Score: 0.005
  30. Preoperative evaluation of patients with recurrent carcinoma of the cervix. Gynecol Oncol. 1972 Nov; 1(1):111-8.
    View in: PubMed
    Score: 0.005
  31. Carcinoma in situ of the cervix. An analysis of 861 patients. Obstet Gynecol. 1972 Mar; 39(3):373-80.
    View in: PubMed
    Score: 0.005
  32. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol. 1991 Jan; 40(1):55-65.
    View in: PubMed
    Score: 0.005
  33. Doxorubicin as an adjuvant following surgery and radiation therapy in patients with high-risk endometrial carcinoma, stage I and occult stage II: a Gynecologic Oncology Group Study. Gynecol Oncol. 1990 Feb; 36(2):166-71.
    View in: PubMed
    Score: 0.004
  34. Prognostic value of peritoneal washings in patients with malignant mixed m?llerian tumors of the uterus. Am J Obstet Gynecol. 1986 Jul; 155(1):83-9.
    View in: PubMed
    Score: 0.003
  35. Intraperitoneal chromic phosphate P 32 suspension therapy of malignant peritoneal cytology in endometrial carcinoma. Am J Obstet Gynecol. 1985 Sep 15; 153(2):191-6.
    View in: PubMed
    Score: 0.003
  36. Risk factors and recurrent patterns in Stage I endometrial cancer. Am J Obstet Gynecol. 1985 Apr 15; 151(8):1009-15.
    View in: PubMed
    Score: 0.003
  37. Survival and patterns of recurrence in cervical cancer metastatic to periaortic lymph nodes (a Gynecologic Oncology Group study). Gynecol Oncol. 1984 Sep; 19(1):8-16.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.